You are here

Research

Scientists argue over access to remaining Ebola hotspots

The slowdown in the West African Ebola epidemic is welcome news and reason to be hopeful—but it’s also creating a new problem. With fewer new cases occurring, it is becoming more and more difficult to test vaccines and drugs. As a result, conflicts are looming over who can test Ebola drugs and vaccines in Guinea and Sierra Leone.

An Ebola treatment unit in Guinea.Samuel Hanryon/MSF

In Guinea, a large consortium that includes Doctors Without Borders (MSF) and the World Health Organization (WHO) vaccinated the first volunteers at risk of Ebola on Monday in a big trial of a vaccine produced by Merck and NewLink Genetics. But the team feels threatened because researchers at the U.S. National Institutes of Health (NIH) are looking to move another vaccine study from Liberia, where the epidemic has come to a virtual standstill, to Guinea.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola whole virus vaccine shown effective, safe in primates

SCIENCE DAILY                                                March 26, 2015

(Scroll down for complete paper.)
An Ebola whole virus vaccine, constructed using a novel experimental platform, has been shown to effectively protect monkeys exposed to the often fatal virus.

The vaccine, described today (March 26, 2015) in the journal Science, was developed by a group led by Yoshihiro Kawaoka, a University of Wisconsin-Madison expert on avian influenza, Ebola and other viruses of medical importance. It differs from other Ebola vaccines because as an inactivated whole virus vaccine, it primes the host immune system with the full complement of Ebola viral proteins and genes, potentially conferring greater protection.

"In terms of efficacy, this affords excellent protection," explains Kawaoka, a professor of pathobiological sciences in the UW-Madison School of Veterinary Medicine and who also holds a faculty appointment at the University of Tokyo. "It is also a very safe vaccine."

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Two experimental Ebola vaccines pass safety test in African trial

REUTERS    by  Sharon Begley                                                                       March 26, 2015

NEW YORK - Two experimental Ebola vaccines, one from GlaxoSmithKline PLC and the other from biotech start-up NewLink Genetics Corp, "appear to be safe" part way through a clinical trial being conducted in Liberia, the U.S. National Institutes of Health (NIH) said on Thursday.

The two vaccines, each given in a single injection, are being tested for safety and efficacy on more than 600 people in Liberia in a mid-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases, a branch of NIH.

The Ebola epidemic that began in West Africa one year ago has killed more than 10,200 people, but a decline in new cases in the most affected countries, Liberia, Guinea and Sierra Leone, has led to hopes that it may be ending.

Based on the encouraging safety results, the study may now advance to the next phase of efficacy testing, in which additional volunteers are injected with the GSK vaccine, the NewLink vaccine, or a dummy shot and assessed to see whether their immune system responds by producing anti-Ebola antibodies.

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola virus not mutating as quickly as thought

SCIENCE NEWS  by Ashley Yaeger                                                      March 26, 2015

(Scroll down for full study.)

The virus causing the current Ebola epidemic in West Africa is not evolving as quickly as some scientists had suggested.

REGULAR RATE  A genetic analysis suggests that the Ebola virus, shown here in orange, is not evolving as fast as expected.

In a paper last August, researchers reported that the virus (Zaire ebolavirus) was altering its genes almost twice as fast as it had during previous Ebola outbreaks in Central Africa (SN: 9/20/14, p. 7). However, a new genetic analysis shows that the virus is mutating at roughly the same rate as in past outbreaks, researchers report online March 26 in Science. The finding suggests the virus has not become more virulent or transmissible during the West Africa outbreak.

Problem, Solution, SitRep, or ?: 

New Ebola trial vaccine 'safe': researchers

AFP                                                                                                   March 25, 2015

Paris - The latest in a string of candidate vaccines against the deadly Ebola virus was proven safe in an early trial in healthy adults in China, its developers said Wednesday.

 But while it triggered an antibody response in test subjects, further trials must be held to establish whether the drug actually protects against Ebola, they said.

Dubbed Ad5-EBOV, the vaccine is the first based on the strain of the Ebola virus behind the west African outbreak, according to a paper published in The Lancet medical journal.

Read complete story.
http://news.yahoo.com/ebola-trial-vaccine-safe-researchers-140735607.html;_ylt=AwrBJR6SwhJVFgkANl3QtDMD

Read Lancet article.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2960553-0/abstract

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Liberians overcome fear to volunteer for Ebola vaccine trial

ASSOCIATED PRESS  by Jpnathan Paye-Layleh             March 22, 2015

MONROVIA, Liberia — Liberians are overcoming their fears of Ebola to volunteer for a vaccine trial...

One year after the World Health Organization declared the Ebola outbreak, vaccine trials are under way in Liberia and Guinea. Sierra Leone will start a trial later this month.

In Liberia, scientists have fanned out across the country to explain the studies and reduce the fear and confusion that have stymied efforts to contain Ebola.

Dr. Stephen Kennedy, the Liberian lead investigator for the study, was among the first people to volunteer for the vaccine trial, getting his injection in front of the media. Similarly, in Guinea, authorities started the study by injecting a series of prominent officials, including the head of the country's Ebola response.

The outreach worked in Liberia, where more than 700 people have volunteered, well beyond the 600 required, according to Kennedy.

Read complete story.
http://news.yahoo.com/liberians-overcome-fear-volunteer-ebola-vaccine-trial-120848405.html

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Deep in the jungle, hunting for the next Ebola outbreak

THE WASHINGTON POST by Kevin Sieff                   March 20, 2015

NOUABALE-NDOKI NATIONAL PARK, Congo Republic — More than 3,000 miles from the fading Ebola crisis in West Africa, a team of U.S.-funded researchers is hunting deep in a remote rain forest for the next outbreak.

Kinshasa, capital of the Democratic Republic of the Congo, is seen just across the Congo River from Brazzaville, capital of Congo Republic. Researchers have come to Congo Republic to explore the role wild pigs may play in the transmission of Ebola from wildlife to humans. Nichole Sobecki/For The Washington Post

 They aren’t looking for infected people. They’re trying to solve one of science’s great mysteries: Where does Ebola hide between human epidemics?

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

FDA panel to discuss Ebola vaccine development in May

REUTERS                                                    March 18, 2015

WASHINGTON ==The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone.

The federal health regulator would discuss the development of vaccines on May 12, it announced on its website on Wednesday.

The resurgence of the virus last year prompted drugmakers from across the world to develop new treatments that are in different stages of studies....

The World Health Organization said it will decide on mass vaccination against the virus in August.

See full story.

http://www.reuters.com/article/2015/03/18/us-health-ebola-fda-idUSKBN0ME1D520150318
-0-

See Federal Register notice of meeting.

https://www.federalregister.gov/articles/2015/03/17/2015-06116/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola vaccine trial to combine GSK, Emergent Bio shots

REUTERS                                                                                                          March 16, 2015

LONDON  - Scientists are to test a new two-shot Ebola vaccine using an experimental shot from Britain's GlaxoSmithKline, which is already in clinical trials in Africa, and a new kind of booster from Emergent BioSolutions.

A health worker, left, injects a man in his arm with an Ebola vaccine in Conakry, Guinea, March 7, 2015. The World Health Organization is starting large-scale testing of an experimental Ebola vaccine in Guinea  to see how effective it might be in preventing future outbreaks of the deadly virus.  (AP Photo/ Youssouf Bah)

The Maryland-based biotech company said on Monday its modified vaccinia Ankara (MVA) Ebola Zaire vaccine would be used in an initial Phase I clinical study to be conducted by researchers at the University of Oxford.

Although Ebola case numbers have fallen to a low level, drug companies are still pushing ahead with efforts to develop an effective vaccine, which may help fight the next outbreak, even if it does not come in time for the current epidemic.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

This smart ‘band-aid’ could help the world beat Ebola

MASHABLE  by  Lance Ulanoff                                                                   March 14, 2015

AUSTIN — The international fight against Ebola is far from over. Just this week, new patients arrived in U.S. hospitals for treatment. But back in Africa where healthcare workers have battled hundreds of cases at a time, officials are struggling to find smart solutions that can help ensure the safety of caregivers, offer more comprehensive and speedy care and add 21st century solutions to their disease-fighting arsenal.

Wearable technology is very close to joining the fight....

Wendy Taylor, Direct of the USAID Center for Accelerating Innovation holds a MultiSense Memory patch prototype

On Saturday at SXSW, The U.S. Agency for International Development (USAID) unveiled both a new biomedical suit and the MultiSense Memory wearable sensor:

Even with a new biomedical suit in the wings, doctors in the field still face significant challenges. “Tools are hard to use in an Ebola setting — you can’t use a stethoscope,” said Taylor.

Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Research
howdy folks